scholarly article | Q13442814 |
P356 | DOI | 10.1021/ML400466P |
P8608 | Fatcat ID | release_7fjkm7wjs5hunj5ru5rsj62w4q |
P932 | PMC publication ID | 4027630 |
P698 | PubMed publication ID | 24900818 |
P50 | author | Charles Jayne | Q88797848 |
P2093 | author name string | Paul J Coleman | |
Joseph P Vacca | |||
Ann E Weber | |||
Robert Chase | |||
Sathesh Bhat | |||
Sony Agrawal | |||
Srikanth Venkatraman | |||
John A Howe | |||
Sylvie Charron | |||
Patrick Beaulieu | |||
Joseph Romano | |||
Unmesh Shah | |||
Nigel J Liverton | |||
Francisco Velázquez | |||
Alexei Buevich | |||
Samuel Chackalamannil | |||
Yongxin Han | |||
John A McCauley | |||
Ian W Davies | |||
Michael T Rudd | |||
Zhuyan Guo | |||
Helmi Zaghdane | |||
Aileen Soriano | |||
Benoit Bachand | |||
Christiane Grisé-Bard | |||
Kimberly Bush | |||
Marie-Christine Brochu | |||
Virender Aulakh | |||
P2860 | cites work | Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase | Q27620480 |
Induced-fit binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3/NS4A protease target | Q27659903 | ||
Diagnosis, management, and treatment of hepatitis C: an update | Q29619682 | ||
Telaprevir for previously untreated chronic hepatitis C virus infection | Q29619800 | ||
The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
The global burden of hepatitis C | Q29620138 | ||
Boceprevir for untreated chronic HCV genotype 1 infection | Q29620617 | ||
MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants | Q34276394 | ||
Direct-acting antiviral agents for hepatitis C virus infection | Q34321440 | ||
Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor | Q34423056 | ||
Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States | Q40249402 | ||
P433 | issue | 3 | |
P304 | page(s) | 264-269 | |
P577 | publication date | 2014-01-09 | |
P1433 | published in | ACS Medicinal Chemistry Letters | Q2819061 |
P1476 | title | Novel Quinoline-Based P2-P4 Macrocyclic Derivatives As Pan-Genotypic HCV NS3/4a Protease Inhibitors | |
P478 | volume | 5 |
Q38714640 | Discovery of MK-8831, A Novel Spiro-Proline Macrocycle as a Pan-Genotypic HCV-NS3/4a Protease Inhibitor |
Q38714156 | Dual therapy of grazoprevir and elbasvir for the treatment of hepatitis C infection |
Q54210704 | Grazoprevir/elbasvir for the treatment of adults with chronic hepatitis C: a short review on the clinical evidence and place in therapy. |
Q34411907 | MK-5172 : a second-generation protease inhibitor for the treatment of hepatitis C virus infection. |
Q26800050 | New era for management of chronic hepatitis C virus using direct antiviral agents: A review |
Q38724091 | Pharmacodynamics and pharmacokinetics of elbasvir and grazoprevir in the treatment of hepatitis C. |
Search more.